GLP-1 dose escalation schedules, four labels side by side

Ozempic (semaglutide) injection

The Ozempic label sets an initiation dosage and then two optional increases, each gated on glycemic control rather than on the calendar alone: “If additional glycemic control is needed after at least 4 weeks” on the current dose.

The same label sets a separate rule for one population: in patients with type 2 diabetes and chronic kidney disease, increase to the 1 mg maintenance dosage after at least 4 weeks on 0.5 mg.

Wegovy (semaglutide)

Wegovy’s ladder is on the clock rather than on a response, and the label prints it as a table of week ranges. It is also the only one of the four whose label covers two dosage forms, so there are two schedules here and they are not related to each other.

For weight reduction in adults the recommended maintenance dosage is 2.4 mg once weekly, with 1.7 mg as the alternative. The label then adds a step above it: for patients who tolerate 2.4 mg for at least 4 weeks and for whom additional weight reduction is clinically indicated, “the dosage may be increased to a maximum dosage of 7.2 mg subcutaneously once weekly.” For cardiovascular risk reduction the maintenance dosage is 2.4 mg or 1.7 mg, and for noncirrhotic MASH with moderate to advanced fibrosis it is 2.4 mg, reducible to 1.7 mg if 2.4 mg is not tolerated.

Mounjaro and Zepbound (tirzepatide)

Both tirzepatide labels start at 2.5 mg once weekly and both move in 2.5 mg increments after at least 4 weeks on the current dose. They differ in where they stop and in what they say about the starting dose.

What the schedules do not cover

The four ladders above describe four FDA-approved products. Some telehealth providers supply compounded semaglutide or compounded tirzepatide instead, and a compounded preparation has no FDA-approved label — so there is no approved escalation schedule to read, no approved strength list, and nothing on this page that describes one. The FDA states plainly that “compounded drugs are not FDA approved” and that “the agency does not review compounded drugs for safety, effectiveness or quality before they are marketed.”

The same FDA page records what has gone wrong when a dose schedule is written outside an approved label: reports of adverse events, “some requiring hospitalization, that may be related to dosing errors associated with compounded injectable semaglutide products”, and further reports involving patients “prescribed compounded semaglutide or tirzepatide products in doses beyond what is in the FDA-approved drug label” — including “increasing the amount more quickly (titration schedule).”

A reader on a compounded product has the schedule their own prescriber wrote, and it is worth asking that prescriber which approved schedule, if any, it follows. Related: what each label says about a missed dose, and what Zepbound’s own trials reported at each of its three maintenance doses.

Sources

See the providers

Once you know the schedule, the boards list the providers who sell each drug on it and what each one publishes.

• Semaglutide providersprovider board

  Compare semaglutide plans, pharmacy details and cancellation terms.

• Tirzepatide providersprovider board

  Compare tirzepatide plans, pharmacy details and cancellation terms.

More, read from the same labels

• First-year GLP-1 costsresearch guide

  A low monthly headline does not tell you what a year of treatment will cost. Compare the same medication and service package, then separate the total you expect to spend from the amount you must pay before treatment begins.

• Cancellation and refundsresearch guide

  Canceling future membership charges, stopping an upcoming medication order and requesting a refund are three different requests. Get a written answer for each one that applies to you.

• Insurance denial documentsresearch guide

  The next step depends on why coverage was denied. A missing document, a formulary restriction and an excluded benefit are different problems. Start with the written decision before paying someone to submit another request.

• Savings and cash-pay eligibilityresearch guide

  A manufacturer savings card and a self-pay offer can have different eligibility rules, even for the same medicine. Match the offer to your coverage and exact product before using its advertised price in your budget.

• Verify your GLP-1 pharmacyresearch guide

  The website taking your payment, the clinician prescribing and the pharmacy dispensing may be different businesses. Identify each one. A recognizable brand or a reassuring badge does not tell you who will fill the prescription.

• Changing GLP-1 providersresearch guide

  Before ending your current service, establish what the new practice needs, what it will charge and when it can evaluate you. Transferring your records does not guarantee that another clinician will continue the same prescription.

• Weight regain after stoppingresearch guide

  Weight regain occurred after treatment withdrawal in studies of semaglutide and tirzepatide. The findings support planning follow-up and affordability before an interruption, but they do not predict exactly what will happen to one person.

• Semaglutide vs tirzepatideresearch guide

  What the four FDA-approved labels say each molecule is, what each is approved to treat, and where the two differ.

• How they workresearch guide

  The receptor each molecule switches on, what the labels say that does to appetite, blood sugar and the stomach, and why one dose lasts a week.

• Is Ozempic insulin?research guide

  What the Ozempic label calls semaglutide, how that differs from insulin, and where insulin appears on these labels as a separate medicine.

• Zepbound vs Ozempicresearch guide

  Four brand names, two molecules and two kinds of approval: which of these products are the same drug, and what each one is actually approved to do.

• Side effect ratesresearch guide

  What each label reports for nausea, vomiting, diarrhea and constipation — and the sentence every label prints above those numbers.

• Hair lossresearch guide

  Which labels report hair loss, the rate against placebo where a trial measured it, and why two of them put no number on it.

• Fatigue and tirednessresearch guide

  Which labels list fatigue, the rate against placebo where a trial measured it, and what each label counts as fatigue.

• Missed dose rulesresearch guide

  The window each label gives for a late dose, and the minimum gap it requires when the injection day changes.

• Drug interactionsresearch guide

  Insulin and sulfonylureas, oral medications, and the oral-contraceptive precaution that appears on two of these four labels and not the other two.

• Buying one onlineresearch guide

  The agency's own warning signs for a telehealth GLP-1 seller, its 28-day vial rule, and what it says about drugs that arrive warm.

• Zepbound by doseresearch guide

  What each Zepbound dose achieved in the trials printed in its label, what the label says about choosing a maintenance dose, and what the higher doses cost in side effects.

• Zepbound at 3 monthsresearch guide

  What does the Zepbound label report about three-month weight loss and maintenance dosing?

• Injecting tirzepatideresearch guide

  The injection sites, the rotation rule and the steps for the single-dose pen, the KwikPen and the vial and syringe, exactly as the FDA-approved Instructions for Use give them.

• Refrigeration and storageresearch guide

  How cold each pen is kept, how many days it can spend at room temperature, and what the labels say about heat and freezing.

• Who should not take oneresearch guide

  The boxed warning every one of these labels carries, the two contraindications, and which warnings appear on which product.